Stimulation of TNF-α production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - A novel immunomodulator with potential application in tumour immunotherapy

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 3, 2002, Pages 213-222

  Lasek, Witold ^a   Świtaj, Tomasz ^a   Sieńko, Jacek ^a   Kasprzycka, Monika ^a   Basak, Grzegorz ^a   Mikłaszewicz, Piotr ^a   Maj, Małgorzata ^a   Nowis, Dominika ^a   Grzela, Tomasz ^a   Goła̧b, Jakub ^a   Młynarczuk, Izabela ^a   Jalili, Ahmad ^a   Kamińska, Bozena ^b   Dziembowska, Magdalena ^b   Czajkowski, Krzysztof ^a   Nowaczyk, Maria ^a   Górska, Agata ^c   Kazimierczuk, Zygmunt ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Adamantane; TNF ; Tumour immunotherapy

Indexed keywords

2 (1 ADAMANTYLAMINO) 6 METHYLPYRIDINE; ANTIINFLAMMATORY AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CANCER VACCINE; COLLAGEN TYPE 4; DEXAMETHASONE; DEXAVEN; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; LIPOPOLYSACCHARIDE; MESSENGER RNA; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL ADHESION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; ELECTROPHORETIC MOBILITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INCUBATION TIME; MELANOMA CELL; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ADAMANTANE; AMINOPYRIDINES; ANIMALS; FEMALE; HUMANS; MELANOMA; MICE; NF-KAPPA B; OVARIAN NEOPLASMS; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036042731     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0496-5     Document Type: Article

References (45)

1. Tumour necrosis factors: Developments during the last decade
2. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II
3. Tumor necrosis factor and DNA topoisomerase II inhibitors in human ovarian cancer: Potential role in chemotherapy
4. Dichotomy of glucocorticoid action in the immune system
5. Lipopolysaccharide-induced interleukin-10 in mice: Role of endogenous tumor necrosis factor-α
6. New insights into the molecular basis of glucocorticoid action
7. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages
8. The role of MyD88 and TLR in the LPS-mimetic activity of taxol
9. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
10. An endotoxin-induced serum factor that causes necrosis of tumors
11. Taming TNF: Strategies to restrain this proinflammatory cytokine
12. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
13. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease
14. Depressed immune surveillance against cancer: Role of deficient T cell: Extracellular matrix interactions
15. Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-α production in vitro
16. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice
17. Tumor necrosis factor: Clinical relevance
18. Stimulation of tumors to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
19. Dexamethasone suppresses release of soluble TNF receptors by human monocytes concurrently with TNF-α suppression
20. Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidine on solid tumors in mice
21. NF-κB at the crossroads of life and death
22. Adamantylamino-pyrimidines and -pyridines are potent inducers of tumor necrosis factor-α
23. Influenza
24. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia
25. Signal transduction and gene regulation: The nuclear response to cAMP
26. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results
27. Antitumor effects of the combination therapy with TNF-α gene-modified tumor cells and interleukin 12 in a melanoma model in mice
28. Clinical applications of TNF-α in cancer
29. Lectin-deficient TNF mutants display comparable antitumor but reduced pro-metastatic potential as compared to the wild-type molecule
30. Thalidomide as an emerging immunotherapeutic agent
31. Synthesis, structure and tumor necrosis factor-α production enhancing properties of novel adamantylamino heterocyclic derivatives
32. Nuclear factor of activated T cells (NFAT) as a new component of the signal transduction pathway in glioma cells
33. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
34. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression
35. Cytokine mRNA expression pattern in human esophageal cancer cell lines
36. Synthesis and antimicrobial activity of new adamantane derivatives I
37. Immunological gene therapy with ex vivo gene-modified tumor cells; a critique and a reappraisal
38. OKT3-induced cytokine mRNA expression in human peripheral blood mononuclear cells measured by polymerase chain reaction
39. N-alkylphthalimides: Structural requirement of thalidomidal action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor alpha production by human leukemia HL-60 cells
40. Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro
41. Tumor necrosis factor expression by human ovarian carcinoma in vivo
42. Immunomodulatory properties of recombinant murine and human tumor necrosis factor
43. Anti-TNF agents in Crohn's disease
44. In vitro antitumor and antimicrobial activities of N-substituents of maleimide by adamantane and diamantane
45. Glucocorticoids and immune function: Unknown dimensions and new frontiers